OBJECTIVE: Our main objective was to compare the regulation of cortisol production within omental (Om) and abdominal subcutaneous (Abd sc) human adipose tissue. METHODS AND PROCEDURES: Om and Abd sc adipose tissue were obtained at surgery from subjects with a wide range of BMI. Hydroxysteroid dehydrogenase (HSD) activity ((3)H-cortisone and (3)H-cortisol interconversion) and expression were measured before and after organ culture with insulin and/or dexamethasone. RESULTS: Type 1 HSD (HSD1) mRNA and reductase activity were mainly expressed within adipocytes and tightly correlated with adipocyte size within both depots. There was no depot difference in HSD1 expression or reductase activity, while cortisol inactivation and HSD2 mRNA expression (expressed in stromal cells) were higher in Om suggesting higher cortisol turnover in this depot. Culture with insulin decreased HSD reductase activity in both depots. Culture with dexamethasone plus insulin compared to insulin alone increased HSD reductase activity only in the Om depot. This depot-specific increase in reductase activity could not be explained by an alteration in HSD1 mRNA or protein, which was paradoxically decreased. However, in Om only, hexose-6-phosphate dehydrogenase (H6PDH) mRNA levels were increased by culture with dexamethasone plus insulin compared to insulin alone, suggesting that higher nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) production within the endoplasmic reticulum (ER) contributed to the higher HSD reductase activity. DISCUSSION: We conclude that in the presence of insulin, glucocorticoids cause a depot-specific increase in the activation of cortisone within Om adipose tissue, and that this mechanism may contribute to adipocyte hypertrophy and visceral obesity.
OBJECTIVE: Our main objective was to compare the regulation of cortisol production within omental (Om) and abdominal subcutaneous (Abd sc) human adipose tissue. METHODS AND PROCEDURES: Om and Abd sc adipose tissue were obtained at surgery from subjects with a wide range of BMI. Hydroxysteroid dehydrogenase (HSD) activity ((3)H-cortisone and (3)H-cortisol interconversion) and expression were measured before and after organ culture with insulin and/or dexamethasone. RESULTS: Type 1 HSD (HSD1) mRNA and reductase activity were mainly expressed within adipocytes and tightly correlated with adipocyte size within both depots. There was no depot difference in HSD1 expression or reductase activity, while cortisol inactivation and HSD2 mRNA expression (expressed in stromal cells) were higher in Om suggesting higher cortisol turnover in this depot. Culture with insulin decreased HSD reductase activity in both depots. Culture with dexamethasone plus insulin compared to insulin alone increased HSD reductase activity only in the Om depot. This depot-specific increase in reductase activity could not be explained by an alteration in HSD1 mRNA or protein, which was paradoxically decreased. However, in Om only, hexose-6-phosphate dehydrogenase (H6PDH) mRNA levels were increased by culture with dexamethasone plus insulin compared to insulin alone, suggesting that higher nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) production within the endoplasmic reticulum (ER) contributed to the higher HSD reductase activity. DISCUSSION: We conclude that in the presence of insulin, glucocorticoids cause a depot-specific increase in the activation of cortisone within Om adipose tissue, and that this mechanism may contribute to adipocyte hypertrophy and visceral obesity.
Authors: Britt G Gabrielsson; Louise E Olofsson; Anders Sjögren; Margareta Jernås; Anna Elander; Malin Lönn; Mats Rudemo; Lena M S Carlsson Journal: Obes Res Date: 2005-04
Authors: Iwona J Bujalska; Nicole Draper; Zoi Michailidou; Jeremy W Tomlinson; Perrin C White; Karen E Chapman; Elizabeth A Walker; Paul M Stewart Journal: J Mol Endocrinol Date: 2005-06 Impact factor: 5.098
Authors: Thekkepat C Sandeep; Ruth Andrew; Natalie Z M Homer; Robert C Andrews; Ken Smith; Brian R Walker Journal: Diabetes Date: 2005-03 Impact factor: 9.461
Authors: Raoul Desbriere; Vincent Vuaroqueaux; Vincent Achard; Sandrine Boullu-Ciocca; Martin Labuhn; Anne Dutour; Michel Grino Journal: Obesity (Silver Spring) Date: 2006-05 Impact factor: 5.002
Authors: Maria E Trujillo; Mi-Jeong Lee; Sean Sullivan; Jianying Feng; Stephen H Schneider; Andrew S Greenberg; Susan K Fried Journal: J Clin Endocrinol Metab Date: 2006-01-10 Impact factor: 5.958
Authors: Robert S Lindsay; Deborah J Wake; Saraswathy Nair; Joy Bunt; Dawn E W Livingstone; Paska A Permana; P Antonio Tataranni; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2003-06 Impact factor: 5.958
Authors: Stefan Engeli; Jana Böhnke; Mareike Feldpausch; Kerstin Gorzelniak; Ute Heintze; Jürgen Janke; Friedrich C Luft; Arya M Sharma Journal: Obes Res Date: 2004-01
Authors: Guoping Li; Antonio Hernandez-Ono; Rosanne M Crooke; Mark J Graham; Henry N Ginsberg Journal: Metabolism Date: 2011-12-29 Impact factor: 8.694
Authors: Sean M Hartig; Bin He; Justin Y Newberg; Scott A Ochsner; David S Loose; Rainer B Lanz; Neil J McKenna; Benjamin M Buehrer; Sean E McGuire; Marco Marcelli; Michael A Mancini Journal: Chem Biol Date: 2012-09-21
Authors: P Morentin Gutierrez; A Gyte; J deSchoolmeester; P Ceuppens; J Swales; C Stacey; J W Eriksson; M Sjöstrand; C Nilsson; B Leighton Journal: Br J Pharmacol Date: 2015-10-08 Impact factor: 8.739
Authors: P Mauriège; D R Joanisse; A Cartier; I Lemieux; J Bergeron; S Biron; P Marceau; D Richard Journal: Adipocyte Date: 2015-12-08 Impact factor: 4.534
Authors: P Mauriège; D R Joanisse; S CasparBauguil; A Cartier; I Lemieux; J Bergeron; S Biron; P Marceau; D Richard Journal: J Physiol Biochem Date: 2015-10-10 Impact factor: 4.158
Authors: Therése Andersson; Kotryna Simonyte; Ruth Andrew; Magnus Strand; Jonas Burén; Brian R Walker; Cecilia Mattsson; Tommy Olsson Journal: PLoS One Date: 2009-12-29 Impact factor: 3.240